A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to create a predictive tool using neutralizing antibody titers for evaluating monoclonal antibody efficacy in COVID-19 prevention.
Utilized data from the CANOPY trial, focusing on pemivibrart over 12 months
Developed a Cox proportional hazards model incorporating time-varying covariates
Estimated serum virus neutralizing activity at two-week intervals
Efficacy increased in a non-linear manner with antibody titer levels
Predicted efficacy was lower for immunocompromised individuals compared to non-immunocompromised
A neutralizing titer of 1:500 indicated 50% efficacy in immunocompromised and 70% in non-immunocompromised subjects

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Develops a model to predict antibody efficacy in preventing COVID-19, indicating its usefulness for treatment strategies.

No takes yet. Share an insight, caveat, or question.

Yalcin et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share